Citron Research published on agilon health (NYSE: AGL — $7.13 billion), a Medicare billing and physician management services company. Citron highlighted that the company “is on track to lose $70 million in 2022” and said its best days are behind it “as their business model unknowingly got torpedoed by the Supreme Court of the United States without Wall Street noticing.” Specifically, Citron believes the Supreme Court’s decision to not hear UnitedHealthcare v. Secretary of Health and Human Services will harm agilon health because the market for Medicare overpayments will be diminished.
- 2022-12-05: $18.13
- 2023-01-30: $20.61
2026-01-30 USD 0.8322
Last updated: 2026-03-07 by automated standardization process
last updated: